Patents by Inventor Jesse Baumgold

Jesse Baumgold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICROARRAY SLIDES THAT ENHANCE FLUORESCENT SIGNALS VIA PLASMONIC INTERACTION
    Publication number: 20180045644
    Abstract: The invention describes generating and use of a multi-layer plasmonic slide, wherein the plasmonic slide comprises at least 6 layers of metallic nanoparticles that can enhance the detection of fluorescent signals and wherein the plasmonic slide can be printed as a microarray of any size. The microarray containing the plasmonic slide can further be printed with a protein, a glycan, or an antibody. The multi-layer plasmonic slide is capable of detecting proteins, polynucleotides, and/or glycans at orders of magnitude lower concentration than non-plasmonic substrates.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 15, 2018
    Applicants: Biochemistry
    Inventor: Jesse Baumgold
  • Compounds for cancer imaging and therapy
    Patent number: 6517811
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: February 11, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Benzamide compounds for cancer imaging and therapy
    Patent number: 6447748
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: September 10, 2002
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Compounds for cancer imaging and therapy
    Publication number: 20010006619
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Application
    Filed: January 5, 2001
    Publication date: July 5, 2001
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Benzamide compounds containing a heterocyclic ring for tumor imaging and therapy
    Patent number: 6015543
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Benzamide compounds for cancer imaging and therapy
    Patent number: 5993777
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Methods for cancer imaging and therapy using benzamine compounds
    Patent number: 5911970
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: June 15, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl]amide congeners as muscarinic agents
    Patent number: 5274121
    Abstract: Compounds, which are muscarinic agents, having the formula ##STR1## wherein Am is --N(R).sub.a).sub.2, --N(R.sub.a).sub.3.sup.+ I.sup.-, --N (CH.sub.2).sub.n', or ##STR2## n' is an integer from 2 to 7 and R.sub.a is an alkyl having 1 to 4 carbon atoms, and each R.sub.a may be the same or different wherein the other substituents are defined hereinbelow.
    Type: Grant
    Filed: April 30, 1992
    Date of Patent: December 28, 1993
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Barton J. Bradbury, Jesse Baumgold